Primary central nervous system lymphoma: essential points in diagnosis and management

PAYDAŞ S.

MEDICAL ONCOLOGY, cilt.34, sa.4, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 34 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s12032-017-0920-7
  • Dergi Adı: MEDICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Primary central nervous system lymphoma, Pathogenesis, Prognosis, Management, Chemotherapy, Radiotherapy, PRIMARY CNS LYMPHOMA, HIGH-DOSE METHOTREXATE, STEM-CELL TRANSPLANTATION, PRIMARY VITREORETINAL LYMPHOMA, WHOLE-BRAIN RADIOTHERAPY, INTERNATIONAL EXTRANODAL LYMPHOMA, PRIMARY INTRAOCULAR LYMPHOMA, RECURRENT PRIMARY CNS, NON-HODGKINS-LYMPHOMA, MULTICENTER PHASE-II
  • Çukurova Üniversitesi Adresli: Evet

Özet

Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin lymphoma. PCNSL is defined as lymphoma involving the brain, leptomeninges, eyes, or spinal cord without evidence of lymphoma outside the CNS. Treatment includes induction with chemotherapy and consolidation with whole-brain radiotherapy or high-dose chemotherapy supported by autologous stem cell transplantation. High-dose methotrexate is the most important drug in cases with PCNSL, and this drug will be used in combination with small molecules, BTK inhibitors, new monoclonal antibodies, and checkpoint blockers.